From Endocrine Today:
Data recently published in The Journal of Clinical Endocrinology & Metabolism demonstrated that 12 weeks of statin therapy reduced inflammatory markers, insulin resistance and hyperandrogenemia in women with polycystic ovary syndrome.
Researchers from the University of Hull in the United Kingdom conducted a randomized, double-blind, placebo-controlled trial to determine the effects of statin therapy in women with PCOS.
The study included 40 patients with PCOS and biochemical hyperandrogenemia. Patients were a mean age of 27.7 years. Patients were randomly assigned to atorvastatin 20 mg daily or placebo. After four weeks, two patients from the placebo group and one from the atorvastatin group dropped out due to noncompliance.
After 12 weeks, the researchers reported an absolute reduction in total cholesterol (–26.4% change), LDL cholesterol (–36.6%), triglycerides (–20.9%), free androgen index (–32.7%) and total testosterone (–24.6%) among patients in the atorvastatin group. Sex hormone–binding globulin increased by 13.7% in the atorvastatin group. According to the researchers, patients assigned to placebo did not experience changes in any of these parameters.
Patients in the atorvastatin group had lower serum insulin levels and homeostasis model of insulin resistance (HOMA-IR) compared with the placebo group who experienced increases in both of these parameters.
The researchers reported a link between the reduction of HOMA-IR and improvement in free androgen index (P=.04) in patients assigned to atorvastatin. The reduction of HOMA-IR was also associated with a reduction in triglycerides (P<.01). According to the researchers, there was no linear relationship between the reduction in total cholesterol and improved free androgen index (P=.95), testosterone (P=.69) or sex hormone–binding globulin (P=.22).